{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:33:37Z","timestamp":1785321217425,"version":"3.55.0"},"reference-count":60,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nucl Med"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gastroenteropancreatic (GEP) malignancies are a major cause of cancer-related mortality, with many patients presenting at advanced stages where curative options are limited. Outcomes remain suboptimal, particularly beyond first-line therapy, highlighting the need for novel approaches. Fibroblast activation protein (FAP)-targeted radioligand therapy (RLT) has emerged as a biologically rational strategy that exploits the stromal compartment of desmoplastic tumors. FAPI PET\/CT enables noninvasive assessment of target expression and supports a theranostic framework for patient selection. This review summarizes current clinical evidence on Lutetium-177 (177Lu)-FAP RLT in GEP cancers, including pancreatic, biliary, gastric, and colorectal malignancies. Available data, largely from small and heterogeneous early-phase studies, demonstrate feasibility and acceptable short-term safety, with hematologic toxicity as the main concern. Objective responses are uncommon; however, disease stabilization and symptomatic benefit have been observed in selected patients. Key limitations include variable tumor retention, heterogeneous selection criteria, and the lack of standardized dosimetry and response assessment. Overall, 177Lu-FAP RLT remains investigational but represents a biologically compelling but still clinically unproven biomarker-driven strategy, whose current role is best confined to investigational settings and highly selected patients. Future progress requires optimized ligand design, standardized imaging and dosimetry, and prospective clinical trials to define its clinical role.<\/jats:p>","DOI":"10.1055\/s-0046-1820110","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T22:30:21Z","timestamp":1775946621000},"page":"003-011","source":"Crossref","is-referenced-by-count":1,"title":["Fibroblast Activation Protein-Targeted Radioligand Therapy (FAP RLT) in Gastroenteropancreatic Malignancies: Biological Rationale, Clinical Evidence, and Future Directions"],"prefix":"10.1055","volume":"25","author":[{"given":"Deya' Aldeen","family":"Sweedat","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Ruzzeh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2009-5110","authenticated-orcid":false,"given":"Ahmed Saad","family":"Abdlkadir","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Baghdad Radiotherapy and Nuclear Medicine Hospital, Bab Al-Muadham, Baghdad, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serin","family":"Moghrabi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwah","family":"Abdulrahman","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0978-4716","authenticated-orcid":false,"given":"Akram","family":"Al-Ibraheem","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"03","key":"ref1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"F Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"J D Mizrahi","year":"2020","journal-title":"Lancet"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.21037\/cco-23-94","article-title":"Update on management of pancreatic cancer: a literature review","volume":"13","author":"E CH Lai","year":"2024","journal-title":"Chin Clin Oncol"},{"issue":"13","key":"ref4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2217\/fon-2023-0006","article-title":"Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis","volume":"20","author":"M M Amonkar","year":"2024","journal-title":"Future Oncol"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41571-024-00965-0","article-title":"Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm","volume":"22","author":"P Cirac\u00ec","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2967\/jnumed.124.269215","article-title":"Consensus nomenclature for radionuclide therapy: initial recommendations from nuclear medicine global initiative","volume":"66","author":"A Al-Ibraheem","year":"2025","journal-title":"J Nucl Med"},{"issue":"09","key":"ref7","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.7150\/thno.106108","article-title":"Therapeutic potential of FAPI RLT in oncology: a systematic review","volume":"15","author":"S Ruzzeh","year":"2025","journal-title":"Theranostics"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/j.semnuclmed.2025.06.011","article-title":"The value of FAPI PET\/CT in cholangiocarcinoma and pancreatic cancer: an update","volume":"55","author":"K M Pabst","year":"2025","journal-title":"Semin Nucl Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1202505","DOI":"10.3389\/fonc.2023.1202505","article-title":"Head-to-head comparison of 68Ga-FAPI-04 PET\/CT and 18F-FDG PET\/CT in the evaluation of primary digestive system cancer: a systematic review and meta-analysis","volume":"13","author":"J Ouyang","year":"2023","journal-title":"Front Oncol"},{"issue":"09","key":"ref10","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1007\/s00261-024-04266-z","article-title":"Head-to-head comparison of the diagnostic performance between 68Ga-FAPI-04 PET\/CT and 18F-FDG PET\/CT in colorectal cancer: a systematic review and meta-analysis","volume":"49","author":"Z Zhuang","year":"2024","journal-title":"Abdom Radiol (NY)"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.3390\/ijms26051978","article-title":"Diagnostic performance of radiolabelled FAPI versus [18F]FDG PET imaging in hepato-pancreato-biliary oncology: a systematic review and meta-analysis","volume":"26","author":"R B Henrar","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.21037\/qims-2025-1196","article-title":"The impact of FAPI PET on staging and management in patients with digestive system tumors: a systematic review and meta-analysis","volume":"16","author":"Y Zou","year":"2026","journal-title":"Quant Imaging Med Surg"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"J Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"O Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"32","key":"ref15","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1038\/s41388-018-0275-3","article-title":"Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics","volume":"37","author":"E Pur\u00e9","year":"2018","journal-title":"Oncogene"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00048.2019","article-title":"Diversity and biology of cancer-associated fibroblasts","volume":"101","author":"G Biffi","year":"2021","journal-title":"Physiol Rev"},{"issue":"08","key":"ref17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nrgastro.2012.115","article-title":"The role of stroma in pancreatic cancer: diagnostic and therapeutic implications","volume":"9","author":"M Erkan","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"P P Provenzano","year":"2012","journal-title":"Cancer Cell"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"B C \u00d6zdemir","year":"2014","journal-title":"Cancer Cell"},{"issue":"08","key":"ref20","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","volume":"9","author":"E Elyada","year":"2019","journal-title":"Cancer Discov"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"D Hanahan","year":"2012","journal-title":"Cancer Cell"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/s00259-022-06021-2","article-title":"[68Ga]Ga-FAPI PET for the evaluation of digestive system tumors: systematic review and meta-analysis","volume":"50","author":"D Huang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","author":"F L Giesel","year":"2019","journal-title":"J Nucl Med"},{"issue":"09","key":"ref24","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"T Lindner","year":"2018","journal-title":"J Nucl Med"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/diagnostics13122018","article-title":"FAPI PET\/CT imaging \u2013 an updated review","volume":"13","author":"K R Chandekar","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"09","key":"ref26","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"A Loktev","year":"2018","journal-title":"J Nucl Med"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"C Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"M Eiber","year":"2018","journal-title":"J Nucl Med"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40644-022-00465-3","article-title":"Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms","volume":"22","author":"A Iravani","year":"2022","journal-title":"Cancer Imaging"},{"issue":"08","key":"ref30","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2967\/jnumed.125.269914","article-title":"Meeting upcoming clinical and diagnostic needs in oncologic imaging: a structured reporting system for fibroblast-activation-protein-targeted imaging-FAP-RADS version 1.0","volume":"66","author":"E Novruzov","year":"2025","journal-title":"J Nucl Med"},{"issue":"07","key":"ref31","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies","volume":"50","author":"B M Priv\u00e9","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results","volume":"63","author":"R P Baum","year":"2022","journal-title":"J Nucl Med"},{"issue":"02","key":"ref33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2967\/jnumed.120.244806","article-title":"The latest developments in imaging of fibroblast activation protein","volume":"62","author":"A Altmann","year":"2021","journal-title":"J Nucl Med"},{"issue":"08","key":"ref34","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1007\/s00259-022-05706-y","article-title":"Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond","volume":"49","author":"M Li","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1148\/radiol.2020203275","article-title":"Comparison of 68Ga-FAPI and 18F-FDG uptake in gastric, duodenal, and colorectal cancers","volume":"298","author":"Y Pang","year":"2021","journal-title":"Radiology"},{"issue":"08","key":"ref36","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","article-title":"Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients","volume":"61","author":"C Meyer","year":"2020","journal-title":"J Nucl Med"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/ph14121212","article-title":"First-in-human results on the biodistribution, pharmacokinetics, and dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2","volume":"14","author":"S Ballal","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study","volume":"46","author":"M Assadi","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.2967\/jnumed.125.270186","article-title":"Efficacy and safety of [177Lu]Lu-DOTAGA.Glu.(FAPi)2 therapy in patients with sarcoma","volume":"66","author":"S Ballal","year":"2025","journal-title":"J Nucl Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1737443","DOI":"10.3389\/fnume.2025.1737443","article-title":"Recent clinical advances in fibroblast activation protein targeted radioligand therapy for solid tumors","volume":"5","author":"X Wu","year":"2025","journal-title":"Front Nucl Med"},{"issue":"11","key":"ref41","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"D Zboralski","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/thno.68182","article-title":"Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics","volume":"12","author":"X Wen","year":"2022","journal-title":"Theranostics"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2967\/jnumed.121.262533","article-title":"Albumin binder-conjugated fibroblast activation protein inhibitor radiopharmaceuticals for cancer therapy","volume":"63","author":"M Xu","year":"2022","journal-title":"J Nucl Med"},{"issue":"08","key":"ref44","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-24-3918","article-title":"177Lu-LNC1004 radioligand therapy in patients with end-stage metastatic cancers: a single-center, single-arm, phase II study","volume":"31","author":"H Fu","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"23","key":"ref45","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast activation protein-targeted radioligand therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: first-in-human, dose-escalation study","volume":"29","author":"H Fu","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00259-025-07617-0","article-title":"Safety and efficacy of 177Lu-FAPI-XT radioligand therapy in patients with advanced sarcoma and other cancer entities: first-in-human, dose-escalation study","volume":"53","author":"H Liu","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1097\/RLU.0000000000004021","article-title":"177Lu-FAPI therapy in a patient with end-stage metastatic pancreatic adenocarcinoma","volume":"47","author":"F Kaghazchi","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"06","key":"ref48","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/j.semnuclmed.2025.06.010","article-title":"[177Lu]Lu-FAPI radioligand therapy: emerging horizons and clinical promise in solid tumors: a comprehensive review","volume":"55","author":"A Al-Ibraheem","year":"2025","journal-title":"Semin Nucl Med"},{"issue":"24","key":"ref49","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.3390\/cancers17244019","article-title":"Therapeutic applications of fibroblast activation protein (FAP)-binding radiopharmaceuticals: review of opportunities and challenges","volume":"17","author":"J Maes","year":"2025","journal-title":"Cancers (Basel)"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"111195","DOI":"10.1016\/j.radonc.2025.111195","article-title":"A preliminary study on the safety and efficacy of 177Lu-FAP-2286 in gastrointestinal tumours with positive FAP expression","volume":"213","author":"X Bai","year":"2025","journal-title":"Radiother Oncol"},{"issue":"01","key":"ref51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.semnuclmed.2025.11.022","article-title":"Current status of FAP therapy in solid tumors","volume":"56","author":"S C Siegmund","year":"2026","journal-title":"Semin Nucl Med"},{"issue":"04","key":"ref52","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00259-022-06028-9","article-title":"EANM practice guideline for quantitative SPECT-CT","volume":"50","author":"J C Dickson","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1\u2013update and clarification: from the RECIST committee","volume":"62","author":"L H Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"02","key":"ref54","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"M A Lodge","year":"2016","journal-title":"Radiology"},{"issue":"01","key":"ref55","first-page":"40","article-title":"Initial results and clinical experience of [177Lu]Lu-FAP-2286 for pleural metastases: a single-center retrospective study","volume":"67","author":"L Li","year":"2026","journal-title":"J Nucl Med"},{"issue":"12","key":"ref56","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4240\/wjgs.v12.i12.468","article-title":"Carbohydrate antigen 19-9 - tumor marker: past, present, and future","volume":"12","author":"T Lee","year":"2020","journal-title":"World J Gastrointest Surg"},{"issue":"09","key":"ref57","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.3390\/jcm14093189","article-title":"Carcinoembryonic antigen (CEA): origin, role in oncology, and concentrations in serum and peritoneal fluid","volume":"14","author":"J Niedzielska","year":"2025","journal-title":"J Clin Med"},{"issue":"06","key":"ref58","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3393\/ac.2019.11.13","article-title":"A review of the role of carcinoembryonic antigen in clinical practice","volume":"35","author":"C Hall","year":"2019","journal-title":"Ann Coloproctol"},{"issue":"03","key":"ref59","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"L Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07545-z","article-title":"[177Lu]Lu-FAP-2286 therapy in a case of gastric adenocarcinoma with peritoneal metastasis","author":"K Wang","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["World Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0046-1820110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:36:09Z","timestamp":1777674969000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0046-1820110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":60,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2026,5,1]]},"published-print":{"date-parts":[[2026,3]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0046-1820110","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1450-1147","1607-3312"],"issn-type":[{"value":"1450-1147","type":"print"},{"value":"1607-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}